Drug delivery specialist Gerresheimer boosts 3rd-quarter revenue; MonoSol grabs Canadian patent tied to drug film tech;

> Drug delivery specialist Gerresheimer said that its third-quarter revenue rose 9.9% to €285.1 million. Report

> Montreal-based Theratechnologies ($THER) said that it has found a new growth-hormone releasing factor peptide (GRF) that could be used in treatments for more medical conditions than its existing GRF. Release

> British drug giant AstraZeneca ($AZ) plans to pump $200 million into a new factory in China to produce injectable and oral drugs. Report

> MonoSol Rx has been granted a Canadian patent related to its drug-delivery film products, two of which have recently gained FDA approval. Item

> Depomed, a developer of extended-release drugs, said that its Gralise tablets for once-daily treatment of pain after shingles are now available. Announcement

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.